GLOBAL LIQUID BIOPSY MARKET 2019-2027

MARKET OUTLOOK
According to Triton, the global liquid biopsy market is expected to display a positive market trend over the forecast period of 2019-2027, exhibiting a CAGR of 21.54%.
A liquid biopsy is a non-invasive test used to detect cancer at an early stage and helps in assessing the molecular characteristics of cancer. Liquid biopsy tests help researchers, physicians and surgeons determine an appropriate therapy to improve the life expectancy of cancer patients.
Factors such as the increase in the number of cancer cases among the aging populace, rise in demand for diagnostic centers, increasing number of government initiatives, rise in use of tissue/tumor-agnostic drugs and wide usage of precision medicine are all significantly contributing to the growth of the liquid biopsy market. Opportunities like technological advancements and the rise in number of cancer patients can be leveraged by the industry to reach the projected growth. The lack of skilled professionals and the dearth of reimbursements are some of the challenges faced by this market. Also, high cost of tests and a lack of consensus on SOPs, impede the growth of the market.
REGIONAL OUTLOOK
The global liquid biopsy market spans across the regions of North America, Asia-Pacific, Latin America, Europe and the Middle East & Africa.
Presently, the APAC liquid biopsy market has highest CAGR, and is the fastest-growing market in the world. There is a probability of major market vendors shifting their sales, manufacturing & distribution facilities to the Asia-Pacific in order to benefit from the attractive proposition of easily available labor, lower cost of land & material and access to a large patient base. The end-users can thus avail the vendors’ solutions at extremely low prices. Thus, economic development and growing support from the government, along with a likelihood of major market vendors shifting their operating base to the region, have created new opportunities of the growth of the liquid biopsy market in the Asia-Pacific.
COMPETITIVE OUTLOOK
The companies that have been mentioned in the global liquid biopsy market report are C. R. Bard, Inc. (acquired by Becton, Dickinson and Company), Fischer Medical Technologies LLC, Cook Medical, Inc., Cardinal Health, Inc., Bio-Rad Laboratories, Inc., Planmeca Oy, Becton, Dickinson, QIAGEN N.V., I.M.S. Internazionale Medico Scientifica Srl, Ad-Tech Medical Instrument Corp., Roche Diagnostics Corporation, Cintec Medical Ltd., B. Braun Melsungen AG, Argon Medical Devices, Boston Scientific Corporation and Agilent Technologies, Inc.
Becton, Dickinson and Company (BD) is a med-tech corporation, which is involved in improving the quality of life of patients by providing innovative solutions that help develop medical research & genomics, enhance diagnostics, improve medication management, and promote infection prevention. It is a manufacturer and distributor of medical supplies, devices, laboratory equipment, and diagnostic products worldwide. BD is actively involved in the development, manufacturing & distribution of devices, diagnostic products and laboratory equipment over the globe. The company has two subsidiaries: BD Life Sciences and BD Medical. The client base of the company includes life science researchers, healthcare institutes and public & clinical laboratories. It is present in over 50 countries.

TABLE OF CONTENT
1. GLOBAL LIQUID BIOPSY MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHT
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF RIVALRY
2.4. REGULATORY FRAMEWORK
2.5. KEY MARKET TRENDS
2.6. KEY LIQUID BIOPSY INITIATIVES
2.7. MARKET ATTRACTIVENESS INDEX
2.8. MARKET DRIVERS
2.8.1. CANCER CASES IN OLDER POPULACE ARE SIGNIFICANTLY INCREASING
2.8.2. INCREASE IN DIFFERENT INITIATIVES TAKEN BY THE GOVERNMENT
2.8.3. DIAGNOSTIC CENTERS ARE IN DEMAND
2.8.4. TISSUE/TUMOR-AGNOSTIC DRUGS USAGE ARE INCREASING
2.8.5. RISE IN USAGE OF PRECISION MEDICINE
2.9. MARKET RESTRAINTS
2.9.1. HIGH COST OF TEST
2.9.2. LACK OF A CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPs)
2.10. MARKET OPPORTUNITIES
2.10.1. ADVANCEMENT IN TECHNOLOGY
2.10.2. RISING NUMBER OF CANCER PATIENTS
2.11. MARKET CHALLENGES
2.11.1. LACK OF REIMBURSEMENT
2.11.2. SKILLED PROFESSIONALS ARE QUITE LESS IN NUMBER
3. LIQUID BIOPSY MARKET OUTLOOK - BY THERAPEUTIC APPLICATION
3.1. PROSTATE CANCER
3.2. MELANOMA CANCER
3.3. BREAST CANCER
3.4. COLORECTAL CANCER
3.5. LUNG CANCER
3.6. OTHER TYPES OF CANCER
3.7. NON-ONCOLOGY APPLICATIONS
4. LIQUID BIOPSY MARKET OUTLOOK - BY PRODUCT
4.1. CELL-FREE DNA (CFDNA)
4.2. CIRCULATING TUMOR CELLS (CTCS)
4.3. CIRCULATING TUMOR DNA (CTDNA)
4.4. EXTRACELLULAR VESICLES AND OTHERS
5. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PURPOSE
5.1. MONITORING
5.2. THERAPY GUIDANCE
5.3. EARLY DETECTION/SCREENING
5.4. DIAGNOSIS
6. LIQUID BIOPSY MARKET OUTLOOK - BY END-USER
6.1. HOSPITALS
6.2. PHYSICIANS’ OFFICE LABORATORIES
6.3. CLINICAL DIAGNOSTIC LABORATORIES
7. LIQUID BIOPSY MARKET OUTLOOK - BY ANALYSIS PLATFORM
7.1. MICROARRAY
7.2. NGS
7.3. PROTEOMICS
7.4. PCR
7.5. OTHER ANALYSIS PLATFORMS
8. LIQUID BIOPSY MARKET OUTLOOK - BY BIOMARKER TYPE
8.1. NUCLEIC ACIDS
8.2. PROTEINS
8.3. EXTRACELLULAR VESICLES
8.4. CELLS
9. LIQUID BIOPSY MARKET OUTLOOK - BY CLINICAL APPLICATION
9.1. TREATMENT MONITORING
9.2. PROGNOSIS & REOCCURRENCE MONITORING
9.3. TREATMENT SELECTION
9.4. DIAGNOSIS & SCREENING
10. LIQUID BIOPSY MARKET - REGIONAL OUTLOOK
10.1. NORTH AMERICA
10.1.1. MARKET BY THERAPEUTIC APPLICATION
10.1.2. MARKET BY CLINICAL APPLICATION
10.1.3. MARKET BY BIOMARKER TYPE
10.1.4. MARKET BY ANALYSIS PLATFORM
10.1.5. MARKET BY ANALYSIS PURPOSE
10.1.6. MARKET BY PRODUCT
10.1.7. MARKET BY END-USER
10.1.8. COUNTRY ANALYSIS
10.1.8.1. THE UNITED STATES
10.1.8.2. CANADA
10.2. EUROPE
10.2.1. MARKET BY THERAPEUTIC APPLICATION
10.2.2. MARKET BY CLINICAL APPLICATION
10.2.3. MARKET BY BIOMARKER TYPE
10.2.4. MARKET BY ANALYSIS PLATFORM
10.2.5. MARKET BY ANALYSIS PURPOSE
10.2.6. MARKET BY PRODUCT
10.2.7. MARKET BY END-USER
10.2.8. COUNTRY ANALYSIS
10.2.8.1. THE UNITED KINGDOM
10.2.8.2. FRANCE
10.2.8.3. GERMANY
10.2.8.4. ITALY
10.2.8.5. SPAIN
10.2.8.6. RUSSIA
10.2.8.7. REST OF EUROPE
10.3. ASIA-PACIFIC
10.3.1. MARKET BY THERAPEUTIC APPLICATION
10.3.2. MARKET BY CLINICAL APPLICATION
10.3.3. MARKET BY BIOMARKER TYPE
10.3.4. MARKET BY ANALYSIS PLATFORM
10.3.5. MARKET BY ANALYSIS PURPOSE
10.3.6. MARKET BY PRODUCT
10.3.7. MARKET BY END-USER
10.3.8. COUNTRY ANALYSIS
10.3.8.1. JAPAN
10.3.8.2. CHINA
10.3.8.3. INDIA
10.3.8.4. SOUTH KOREA
10.3.8.5. ASEAN COUNTRIES
10.3.8.6. AUSTRALIA & NEW ZEALAND
10.3.8.7. REST OF ASIA-PACIFIC
10.4. LATIN AMERICA
10.4.1. MARKET BY THERAPEUTIC APPLICATION
10.4.2. MARKET BY CLINICAL APPLICATION
10.4.3. MARKET BY BIOMARKER TYPE
10.4.4. MARKET BY ANALYSIS PLATFORM
10.4.5. MARKET BY ANALYSIS PURPOSE
10.4.6. MARKET BY PRODUCT
10.4.7. MARKET BY END-USER
10.4.8. COUNTRY ANALYSIS
10.4.8.1. BRAZIL
10.4.8.2. MEXICO
10.4.8.3. REST OF LATIN AMERICA
10.5. MIDDLE EAST AND AFRICA
10.5.1. MARKET BY THERAPEUTIC APPLICATION
10.5.2. MARKET BY CLINICAL APPLICATION
10.5.3. MARKET BY BIOMARKER TYPE
10.5.4. MARKET BY ANALYSIS PLATFORM
10.5.5. MARKET BY ANALYSIS PURPOSE
10.5.6. MARKET BY PRODUCT
10.5.7. MARKET BY END-USER
10.5.8. COUNTRY ANALYSIS
10.5.8.1. SAUDI ARABIA
10.5.8.2. TURKEY
10.5.8.3. THE UNITED ARAB EMIRATES
10.5.8.4. SOUTH AFRICA
10.5.8.5. REST OF MIDDLE EAST & AFRICA
11. COMPETITIVE LANDSCAPE
11.1. AGILENT TECHNOLOGIES, INC.
11.2. BOSTON SCIENTIFIC CORPORATION
11.3. ARGON MEDICAL DEVICES, INC.
11.4. B. BRAUN MELSUNGEN AG
11.5. CINTEC MEDICAL LTD.
11.6. ROCHE DIAGNOSTICS CORPORATION
11.7. AD-TECH MEDICAL INSTRUMENT CORP.
11.8. I.M.S. INTERNAZIONALE MEDICO SCIENTIFICA SRL
11.9. QIAGEN N.V.
11.10. BECTON, DICKINSON
11.11. PLANMECA OY
11.12. BIO-RAD LABORATORIES, INC.
11.13. CARDINAL HEALTH, INC.
11.14. COOK MEDICAL, INC.
11.15. FISCHER MEDICAL TECHNOLOGIES LLC
11.16. C. R. BARD, INC. (ACQUIRED BY BECTON, DICKINSON AND COMPANY)
12. RESEARCH METHODOLOGY & SCOPE
12.1. RESEARCH SCOPE & DELIVERABLES
12.1.1. OBJECTIVES OF STUDY
12.1.2. SCOPE OF STUDY
12.2. SOURCES OF DATA
12.2.1. PRIMARY DATA SOURCES
12.2.2. SECONDARY DATA SOURCES
12.3. RESEARCH METHODOLOGY
12.3.1. EVALUATION OF PROPOSED MARKET
12.3.2. IDENTIFICATION OF DATA SOURCES
12.3.3. ASSESSMENT OF MARKET DETERMINANTS
12.3.4. DATA COLLECTION
12.3.5. DATA VALIDATION & ANALYSIS









LIST OF TABLES
TABLE 1 GLOBAL LIQUID BIOPSY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 2 LIQUID BIOPSY BIOMARKER CLASSES
TABLE 3 GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
TABLE 4 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 5 GLOBAL LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 6 GLOBAL LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 7 GLOBAL LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 8 GLOBAL LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 9 ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 10 DROPLET DIGITAL PCR INDUSTRIES
TABLE 11 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 12 CELL DIFFERENTIATORS
TABLE 13 GLOBAL LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 14 GLOBAL LIQUID BIOPSY MARKET BY REGION 2019-2027 ($ MILLION)
TABLE 15 NORTH AMERICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 16 NORTH AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 17 NORTH AMERICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 18 NORTH AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 19 NORTH AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 20 NORTH AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 21 NORTH AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 22 NORTH AMERICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 23 EUROPE LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 24 EUROPE LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 25 EUROPE LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 26 EUROPE LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 27 EUROPE LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 28 EUROPE LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 29 EUROPE LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 30 EUROPE LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 31 ASIA-PACIFIC LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 32 ASIA-PACIFIC LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 33 ASIA-PACIFIC LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 34 ASIA-PACIFIC LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 35 ASIA-PACIFIC LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 37 ASIA-PACIFIC LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 38 ASIA-PACIFIC LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 39 LATIN AMERICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 40 LATIN AMERICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 41 LATIN AMERICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 42 LATIN AMERICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 43 LATIN AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 44 LATIN AMERICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 45 LATIN AMERICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 46 LATIN AMERICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)
TABLE 47 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY COUNTRY 2019-2027 ($ MILLION)
TABLE 48 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATION 2019-2027 ($ MILLION)
TABLE 49 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY CLINICAL APPLICATION 2019-2027 ($ MILLION)
TABLE 50 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY BIOMARKER TYPE 2019-2027 ($ MILLION)
TABLE 51 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM 2019-2027 ($ MILLION)
TABLE 52 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE 2019-2027 ($ MILLION)
TABLE 53 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY PRODUCT 2019-2027 ($ MILLION)
TABLE 54 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET BY END-USER 2019-2027 ($ MILLION)









LIST OF FIGURES
FIGURE 1 GLOBAL LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 2 RURAL POPULATIONS IN DEVELOPING COUNTRIES 2017 (%)
FIGURE 3 GLOBAL LIQUID BIOPSY MARKET BY PROSTATE CANCER 2019-2027 ($ MILLION)
FIGURE 4 GLOBAL LIQUID BIOPSY MARKET BY MELANOMA CANCER 2019-2027 ($ MILLION)
FIGURE 5 TYPES OF BREAST CANCER
FIGURE 6 GLOBAL LIQUID BIOPSY MARKET BY BREAST CANCER 2019-2027 ($ MILLION)
FIGURE 7 GLOBAL LIQUID BIOPSY MARKET BY COLORECTAL CANCER 2019-2027 ($ MILLION)
FIGURE 8 GLOBAL LIQUID BIOPSY MARKET BY LUNG CANCER 2019-2027 ($ MILLION)
FIGURE 9 GLOBAL LIQUID BIOPSY MARKET BY OTHER TYPES OF CANCER 2019-2027 ($ MILLION)
FIGURE 10 GLOBAL LIQUID BIOPSY MARKET BY NON-ONCOLOGY APPLICATION 2019-2027 ($ MILLION)
FIGURE 11 GLOBAL LIQUID BIOPSY MARKET BY CELL-FREE DNA (CFDNA) 2019-2027 ($ MILLION)
FIGURE 12 GLOBAL LIQUID BIOPSY MARKET BY CIRCULATING TUMOR CELLS (CTCS) 2019-2027 ($ MILLION)
FIGURE 13 GLOBAL LIQUID BIOPSY MARKET BY CIRCULATING TUMOR DNA (CTDNA) 2019-2027 ($ MILLION)
FIGURE 14 GLOBAL LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES AND OTHERS 2019-2027 ($ MILLION)
FIGURE 15 GLOBAL LIQUID BIOPSY MARKET BY MONITORING 2019-2027 ($ MILLION)
FIGURE 16 GLOBAL LIQUID BIOPSY MARKET BY THERAPY GUIDANCE 2019-2027 ($ MILLION)
FIGURE 17 GLOBAL LIQUID BIOPSY MARKET BY EARLY DETECTION/SCREENING 2019-2027 ($ MILLION)
FIGURE 18 GLOBAL LIQUID BIOPSY MARKET BY DIAGNOSIS 2019-2027 ($ MILLION)
FIGURE 19 GLOBAL LIQUID BIOPSY MARKET BY HOSPITALS 2019-2027 ($ MILLION)
FIGURE 20 GLOBAL LIQUID BIOPSY MARKET BY PHYSICIANS’ OFFICE LABORATORIES 2019-2027 ($ MILLION)
FIGURE 21 GLOBAL LIQUID BIOPSY MARKET BY CLINICAL DIAGNOSTIC LABORATORIES 2019-2027 ($ MILLION)
FIGURE 22 GLOBAL LIQUID BIOPSY MARKET BY MICROARRAY 2019-2027 ($ MILLION)
FIGURE 23 GLOBAL LIQUID BIOPSY MARKET BY NGS 2019-2027 ($ MILLION)
FIGURE 24 GLOBAL LIQUID BIOPSY MARKET BY PROTEOMICS 2019-2027 ($ MILLION)
FIGURE 25 GLOBAL LIQUID BIOPSY MARKET BY PCR 2019-2027 ($ MILLION)
FIGURE 26 GLOBAL LIQUID BIOPSY MARKET BY OTHER ANALYSIS PLATFORM 2019-2027 ($ MILLION)
FIGURE 27 GLOBAL LIQUID BIOPSY MARKET BY NUCLEIC ACIDS 2019-2027 ($ MILLION)
FIGURE 28 GLOBAL LIQUID BIOPSY MARKET BY PROTEINS 2019-2027 ($ MILLION)
FIGURE 29 GLOBAL LIQUID BIOPSY MARKET BY EXTRACELLULAR VESICLES 2019-2027 ($ MILLION)
FIGURE 30 GLOBAL LIQUID BIOPSY MARKET BY CELLS 2019-2027 ($ MILLION)
FIGURE 31 GLOBAL LIQUID BIOPSY MARKET BY TREATMENT MONITORING 2019-2027 ($ MILLION)
FIGURE 32 GLOBAL LIQUID BIOPSY MARKET BY PROGNOSIS & REOCCURRENCE MONITORING 2019-2027 ($ MILLION)
FIGURE 33 GLOBAL LIQUID BIOPSY MARKET BY TREATMENT SELECTION 2019-2027 ($ MILLION)
FIGURE 34 GLOBAL LIQUID BIOPSY MARKET BY DIAGNOSIS & SCREENING 2019-2027 ($ MILLION)
FIGURE 35 NORTH AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 36 THE UNITED STATES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 37 NEW CANCER CASES & CANCER DEATHS IN THE US 2016-2020 (PER 100,000 PEOPLE)
FIGURE 38 CANADA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 39 EUROPE LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 40 THE UNITED KINGDOM LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 41 FRANCE LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 42 GERMANY LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 43 ITALY LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 44 SPAIN LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 45 RUSSIA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 46 REST OF EUROPE LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 48 JAPAN LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 49 CHINA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 50 INDIA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 51 SOUTH KOREA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 52 AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 53 ASEAN COUNTRIES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 54 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 55 LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 56 BRAZIL LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 57 MEXICO LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 58 REST OF LATIN AMERICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 59 MIDDLE EAST AND AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 60 SAUDI ARABIA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 61 TURKEY LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 62 UNITED ARAB EMIRATES LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 63 SOUTH AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)
FIGURE 64 REST OF MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET 2019-2027 ($ MILLION)